Clinical Trial: Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402213) titled 'Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.' on Jan. 28.

Brief Summary: This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Chronic Spontaneous Urticaria

Intervention: DRUG: JYB1904

300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from Day 1 to Week 48.

DRUG: Placebo+JYB1904

Placebo administered SC on D1 and W12; 300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from W24 to W48.

Recruitment Status: NOT_YET_R...